作　　者： (周美兰）; (景蕊）; (赵丽娟）; (于艳）; (李洋平）; (王鹏波）; (何丽洁）; (许国双）;

机构地区： 第四军医大学西京医院肾脏内科,西安710032

出　　处： 《陕西医学杂志》 2017年第9期1266-1267,1272,共3页

摘　　要： 目的:探讨雷公藤多苷联合缬沙坦治疗糖尿病肾病的临床疗效。方法:将196例糖尿病肾病患者随机分为对照组和治疗组,对照组99例在常规化治疗的基础上,给予缬沙坦口服;治疗组97例在对照组的基础上,联合口服雷公藤多苷,观察比较两组患者治疗前后尿常规和血常规等变化,并观察其不良反应。结果:治疗后,两组患者尿常规和血常规等指标改善均优于治疗前(P<0.05)。其中24h尿蛋白低于治疗前,而血浆白蛋白水平高于治疗前,且治疗组24h尿蛋白的降低效果显著优于对照组(P<0.05)。未出现严重的不良反应。结论:雷公藤多苷联合缬沙坦能降低糖尿病肾病的尿蛋白水平,从而延缓糖尿病肾病的进展,安全有效。 Objective： To observe the therapeutic effect of tripterygium glycosides in combination with valsartan on diabetic nephropathy.Methods： 196 patients with diabetic nephropathy were randomly divided into twogroups.The control group was orally given valsartan-and the treatment group was orally give tripterygium glycosides.Urine and blood routine index, and adverse reaction were observed.Results： After the treatment, urine and blood routine index were improved.Compared with the control group, the 24-hour urine protein and albumin the treatment group were significantly changed （P〈0.05）.Serious adverse reactions was not appeared in the treatment.Conclusion： Tripterygium glycosides in combination with valsartan is effective and safe to diabetic nephropathy, which is worth clinical promotion.

关 键 词： 糖尿病肾病 药物疗法 雷公藤属 治疗应用 缬沙坦